Effects of benztropine on behavioral and toxic effects of cocaine: Comparison with atropine and the selective dopamine uptake inhibitor 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-propyl)-piperazine

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 198-206

  Acri, Jane B ^a   Seidleck, Brian K ^a   Witkin, Jeffrey M ^a  

^a NIDA Addiction Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; ATROPINE; BENZATROPINE MESILATE; COCAINE; DOPAMINE UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG MIXTURE; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NARCOTIC DEPENDENCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ATROPINE; BEHAVIOR, ANIMAL; BENZTROPINE; COCAINE; DISCRIMINATION LEARNING; DOPAMINE UPTAKE INHIBITORS; MALE; MICE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES;

EID: 0030423696     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. ACRI, J. B., SEIDLECK, B. AND WITKIN, J. M.: Effects of dopamine uptake inhibitors on behavioral and toxic effects of cocaine. In NIDA Research Monograph, No. 141, Problems in Drug Dependence, p. 441, U.S. Government Printing Office, Washington, 1994.
2. 3H]BTCP in rat caudate membranes. J. Pharmcol. Exp. Ther. 268: 1462-1475, 1994.
3. 3H]GBR 12935 binding in vitro to rat striatal membranes: Labeling of the dopamine uptake complex. J. Neurochem. 48: 1887-1896, 1987.
4. BERGER, P., ELSWORTH, J. D., REITH, M. E. A., TANEN, D. AND ROTH, R. H.: Complex interaction of cocaine with dopamine uptake carrier. Eur. J. Pharmacol. 176: 251-252, 1990.
5. BERGER, P., GAWIN, F. AND KOSTEN, T. R.: Treatment of cocaine abuse with mazindol. Lancet i: 283, 1989.
6. BERGMAN, J., MADRAS, B. K., JOHNSON, S. E. AND SPEALMAN, R. D.: Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther. 251: 150-155; 1989.
7. BROADBENT, J., MICHAEL, E. K., RIDDLE, E. E. AND APPEL, J. B., Involvement of dopamine uptake in the discriminative stimulus effects of cocaine Behav. Pharmacol. 2: 187-197, 1991.
8. COLPAERT, F. C., NIEMEGEERS, C. J. E. AND JANSSEN, P. A. J.: Discriminative stimulus properties of cocaine: Neuropharmacological characteristics as derived from stimulus generalization experiments. Pharmacol. Biochem. Behav. 10: 535-546; 1979.
9. COYLE, J T. AND SNYDER, S. H.: Antiparkinsonian drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science (Wash. DC) 166: 899-901, 1969.
10. CUNNINGHAM, K. A. AND CALLAHAN, P. M.: Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology 104:177-180, 1991.
11. 3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains. Neurochem. Res. 19: 201-208, 1994.
12. FARNEBO, L.-O., FUXE, K., HAMBERGER, B. AND LJUNGDAHL, H.: Effect of some antiparkinsonian drugs on catecholamine neurons. J. Pharm. Pharmacol. 22: 733-737, 1970.
13. FINNEY, D. J.: Statistical Methods in Biological Assay, 2nd ed., Hafner, New York, 1964.
14. GALAMBOS, É., PFEIFER, A. K., GYÖRGY, L. AND MOLNÁR, J.: Study on the excitation induced by amphetamine, cocaine and α-methyltryptamine. Psychopharmacologia 11: 122-129, 1967.
15. GIROS, B., WANG, Y. M., SUTER, S., MCLESKEYS, S. B., PIFL, C. AND CARON, M.: Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269: 15985-15988, 1994.
16. GOLDSCHMIDT, P. L., SAVARY, L. AND SIMON P.: Comparison of the stimulatory effects of eight antiparkinsonian drugs. Prog Neuropsychopharmacol. Biol. Psychiatry 8: 257-261, 1984.
17. GOLLUB L. R.: The relations among measures of performance on fixed-interval schedules. J. Exp. Anal. Behav. 7: 337-343, 1964.
18. 3H]1-[1-(2-thienyl)cyclohexyl]piperidine binding site (PCP site 2) of guinea pig brain. Synapse 16: 59-65, 1994.
19. HEIKKILA, R E., ORLANSKY, H. AND COHEN, G.: Studies on the distinction between uptake inhibition and release of dopamine in rat brain tissue slices. Biochem. Pharmacol. 24: 847-852, 1975.
20. HORN, A. S.: Dopamine uptake: A review of progress in the last decade. Prog. Neurobiol. 34: 387-400, 1990.
21. HUSSEY, J. S.: The effect of low doses of d-amphetamine on drug-induced hyperactivity in the mouse. Psychopharmacology 81: 327-331, 1983.
22. IZENWASSER, S. I., NEWMAN, A. H. AND KATZ, J. L.: Cocaine and several σ receptor ligands inhibit dopamine uptake in rat caudate-putamen. Eur. J. Pharmacol. 243: 201-205, 1993.
23. IZENWASSER, S. I., TERRY, P., HELLER, B., WITKIN, J. M. AND KATZ, J. L.: Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors. Eur. J. Pharmacol. 263: 277-283, 1994.
24. JAFFE, J. H.: Pharmacological agents in treatment of drug dependence. In Psychopharmacology: The Third Generation of Progress, ed. by H. Y. Meltzer, pp. 1605-1616, Raven Press, New York, 1987.
25. JAFFE, J. H., WITKIN, J. M., GOLDBERG, S. R. AND KATZ, J. L.: Potential toxic interactions of cocaine and mazindol. Lancet ii: 111, 1989.
26. 3H]mazindol binding sites from alkylation by N-ethylmaleimide Eur. J. Pharmacol. 227: 411-415, 1992.
27. KENNEDY, L. T. AND HANBAUER, I.: Sodium-sensitive cocaine binding to rat striatal membrane: Possible relationship to dopamine uptake sites. J. Neurochem. 41: 172-178, 1983.
28. KLEBER, H. D.: Pharmacotherapy, current and potential for the treatment of cocaine dependence. Clin. Neuropharmacol. 18: Suppl. 1, S96-S109, 1995.
29. KUHAR, M. J., RITZ, M. C. AND BOJA, J. W.: The dopamine hypothesis of the reinforcing effects of cocaine. Trends Neurosci. 14: 299-302, 1991.
30. LAMB, R. J. AND GRIFFITHS, R. R.: Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine, and imipramine. Psychopharmacology 102: 183-190, 1990.
31. LARSON, E. W., PFENNING, M. A. AND RICHELSON, E.: Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart. Psychopharmacology 103: 162-165, 1991.
32. KITAYAMA, S., SHIMADA S., XU, H., MARKHAM, L., DONOVAN, D. M. AND UHL, G. R.: Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. U.S.A. 89: 7782-7785, 1992.
33. LITCHFIELD, J. T. AND WILCOXON, F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 95: 99-113, 1949.
34. MACVICAR, K.: Abuse of antiparkinsonian drugs by psychiatric patients. Am. J. Psychiatry 134: 809-811, 1977.
35. 3H]cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 251: 131-141, 1989.
36. MCKEARNEY, J. W.: Effects of dopamine uptake inhibitors on schedule-controlled behavior in the squirrel monkey. Psychopharmacology 78: 377-379, 1982.
37. 1 antagonists as behavioral stimulants in the squirrel monkey. Psychopharmacology 86: 380-381, 1985.
38. MELIA, K. F. AND SPEALMAN, R. D.: Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J. Pharmacol. Exp. Ther. 258: 626-632, 1991.
39. MELTZER, P. C., LIANG, A. Y. AND MADRAS, B. K.: The discovery of an unusually selective and novel cocaine analog: Difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. J. Med. Chem. 37: 2001-2010, 1994.
40. MODELL, J. G., TANDON, R. AND BERESFORD, T. P.: Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J. Clin. Psychopharmacol. 9: 347-351, 1989.
41. NEWMAN, A. H., ALLEN, A. C., IZENWASSER, S. AND KATZ, J. L.: Novel 3α-(diphenylmethoxy)tropane analogs: Potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J. Med. Chem. 37:2258-2261, 1994.
42. RAITERI, M., CERRITO, F., CERVONI, A. M. AND LEVI, G.: Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther. 208:195-202, 1979.
43. REITH, M. E. A., COFFEY, L. L., XU, C. AND CHEN, N.-H.: GBR 12909 and 12935 block dopamine uptake into brain synaptic vesicles as well as nerve endings. Eur. J. Pharmacol. 253: 175-178, 1994.
44. REITH, M. E. A. AND SELMECI, G.: Radiolabeling of dopamine uptake sites in mouse striatum: Comparison of binding sites for cocaine, mazindol, and GBR 12935. Naunyn-Schmiedeberg's Arch. Pharmacol. 345: 309-318, 1992.
45. RICHELSON, E: Tricyclic antidepressants: Interactions with histamine and muscarinic acetylcholine receptors. In Antidepressants: Neurochemical, Behavioral, and Clinical Perspectives, ed. by S. J. Enna, J. B. Malick and E. Richelson, pp. 53-73, Raven Press, New York, 1981.
46. ROTHMAN, R. B.: High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. Life Sci. 46: PL17-PL21, 1990.
47. 3H]TCP binding sites in guinea pig brain. In Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Protection, ed. by E. F. Domino and J.-M. Kamenka, pp. 137-146, NPP Books, Ann Arbor, 1992.
48. RUBINSTEIN, J. S.: Abuse of anticholinergic drugs. N. Engl. J. Med. 299: 834, 1978.
49. SCHEEL-KRÜGER, J.: Behavioural and biochemical comparison of amphetamine derivatives, cocaine, benztropine and tricyclic anti-depressant drugs. Eur J. Pharmacol. 18: 63-73, 1972.
50. SCHUSTER, C. R. AND JOHANSON, C. E.: Relationship between the discriminative stimulus properties and subjective effects of drugs. In Psychopharmacology, Series 4, Transduction Mechanisms of Drug Stimuli, ed. by F. C. Colpaert and R. L. Balster, pp. 161-175, Springer-Verlag, Berlin, 1988.
51. SCHUSTER, C. R. AND SNYDER, M.: NIDA's medication development program-1989. In Problems of Drug Dependence 1989, ed. by L. S. Harris, pp. 64-73, NIDA Research Monograph No. 95, U.S. Government Printing Office, Washington, 1990.
52. SHANNON, H. E. AND PETERS, S. C.: A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. J. Pharmacol. Exp. Ther. 255: 549-553, 1990.
53. SMITH, J. M.: Abuse of antiparkinson drugs: A review of the literature. J. Clin. Psychiatry 41: 351-354, 1980.
54. SNEDECOR, G. W. AND COCHRAS, W. G.: Statistical Methods, 6th ed., Iowa State University Press, Ames, 1967.
55. SPEALMAN, R. D.: Use of cocaine-discrimination techniques for preclinical evaluation of candidate therapeutics for cocaine dependence. In NIDA Research Monograph, No. 119, Problems of Drug Dependence 1991, pp. 175-179, U S. Government Printing Office, Washington, 1992.
56. SPEALMAN, R. D.: Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys. Psychopharmacology 112: 93-99, 1993.
57. SPEALMAN, R. D., MADRAS, B. K. AND BERGMAN, J.: Effects of cocaine and related drugs in nonhuman primates. III. Stimulant effects on schedule-controlled behavior. J. Pharmacol. Exp. Ther. 251: 142-149, 1989.
58. SYVALAHTI, E. K. G., KUNELIUS, R. AND LAURÉN, L.: Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol. Toxicol. 62: 90-94, 1988.
59. TERRY, P. AND KATZ, J. L.: Comparisons between dopamine uptake blockers in rats trained to discriminate cocaine or bupropion. Soc. Neurosci. Abst. 18: 1573, 1992.
60. TIRELLI, E. AND WITKIN, J. M.: Differential effects of direct and indirect dopamine agonists on the induction of gnawing in C57B1/6J mice. J. Pharmacol. Exp. Ther. 237: 7-15, 1995.
61. VAUGEOIS, J.-M., BONNET, J.-J., DUTERTE-BOUCHER, D. AND COSTENTIN, J.. In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur. J. Pharmacol. 230: 195-201, 1993.
62. VAN DER ZEE, P., KOGER, H. S., GOOTJES, J. AND HESPE, W.: Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem. Chim. Therapeut. 15: 363-370, 1980.
63. WIECZORK, W. J. AND KRUK, Z. L.: A quantitative comparison on the effects of benztropine, cocaine and nornifensine on electrically evoked dopamine overflow and rate of re-uptake in the caudate putamen and nucleus accumbens in the rat brain slice. Brain Res. 657: 42-50, 1994.
64. WITKIN, J. M.: Pharmacotherapy of cocaine abuse: Preclinical development. Neurosci. Biobehav. Rev. 18: 121-142, 1994.
65. WITKIN, J. M., ALVARADO-GARCIA, R., LEE, M. A. AND WITKIN, K M.: Nonmuscarinic neurotoxicity of oxotremorine. J. Pharmacol. Exp. Ther. 241: 34-41, 1987.
66. WITKIN, J. M., GENOVESE, R. F., WITKIN, K. M. AND CHIANG, P. K.: Behavioral effects of some diphenyl-substituted antimuscarinics: Comparison with cocaine and atropine. Pharmacol. Biochem. Behav. 41: 377-384, 1992
67. WITKIN, J. M. AND KATZ, J. L.: Preclinical assessment of cocaine toxicity: Mechanisms and pharmacotherapy. In NIDA Research Monograph No. 123, Acute Cocaine Intoxication: Current Methods of Treatment, pp. 44-69, U.S. Government Printing Office, Washington, 1992.
68. WITKIN, J. M., NICHOLS, D. E., TERRY, P. AND KATZ, J. L.: Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections J. Pharmacol. Exp. Ther. 257: 706-713, 1991.
69. WITKIN, J. M. AND TORTELLA, F. C.: Modulators of N-methyl-D-aspartate protect against diazepam- or phenobarbital-resistant cocaine convulsions. Life Sci. 48: PL51-PL56, 1991.
70. WOOLVERTON, W. L. AND JOHNSON, K. M.: Neurobiology of cocaine abuse. Trends Pharmacol. Sci. 13: 193-200, 1992